Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response

Randomized clinical trials demonstrated that CDK4/6 inhibitors are highly effective in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer in combination with endocrine therapy. The use of CDK4/6 inhibitors in clinics is becoming common for patients with HR+...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Care (Basel)
Auteurs principaux: Guarducci, Cristina, Bonechi, Martina, Boccalini, Giulia, Benelli, Matteo, Risi, Emanuela, Di Leo, Angelo, Malorni, Luca, Migliaccio, Ilenia
Format: Artigo
Langue:Inglês
Publié: S. Karger GmbH 2017
Sujets:
Review Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5704709/
https://ncbi.nlm.nih.gov/pubmed/29234249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000484167
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires